Repositioning Candidate Details
| Candidate ID: | R0713 |
| Source ID: | DB05133 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | VP025 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. VP025 may inhibit immune system activation and protect motoneurons from injury. It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function. It is being developed to target the chronic inflammation within the central nervous system that is associated with a number of neurological diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (Lou Gehrig’s disease). It is considered to be a systemic anti-inflammatory and neuroprotective agent. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in alzheimer's disease and inflammatory disorders (unspecified). |
| DrugBank Pharmacology: | VP025 may invoke the body's response ti cell surface phospholipid components, the result of which is an up-regulation of regulatory T cells promoting a suppression of inflammation. VP025 cross the blood-brain barrier, demonstrating potent anti-inflammatory activity and preserving the function of neural pathways necessary for memory and learning. |
| DrugBank MoA: | VP025 is being developed to exert its anti-inflammatory effects using an cell clearance mechanism. VP025, a preparation of phospholipid microparticles containing phosphatidylglycerol, has been shown to exert anti-inflammatory effects in the brain, abrogating age-induced up-regulation of IL-1 beta and IL-1 beta -induced signalling, and reducing the activation of c-Jun N-terminal kinase (JNK), a kinase involved in the inflammatory process. |
| Targets: | Interleukin-1 beta |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|